FDA Device Authorizations Rise in H1 2026, But Approval Timelines Lengthen Significantly
核心洞察
The FDA authorized more medical devices in the first half of 2026 compared to the same period last year, with 23 original premarket approvals granted through June, up from 13 a year prior.
Average time to premarket approval surged to nearly 599 days in H1 2026, a substantial increase from approximately 402 days in 2025, driven by a few outliers.
The 510(k) clearance pathway, the most commonly used route, saw average decision times rise by seven to eight days to roughly 156 days, while total clearances reached 1,669.
The Food and Drug Administration authorized more medical devices in the first half of 2026 than during the same period last year, yet the time required to secure those approvals has lengthened considerably, according to an analysis of FDA data conducted by BTIG (搜索).
Original premarket approvals (PMAs), the agency's most rigorous evaluation pathway for high-risk medical devices, are trending ahead of last year's pace, but the timing to approval is "substantially longer," BTIG (搜索) analyst Ryan Zimmerman wrote in a research note published Monday.
The average time to premarket approval climbed to nearly 599 days in the first half of 2026, compared with approximately 402 days in the prior year. BTIG (搜索) attributed this increase to a few outliers that drove the timeframe upward. In total, the FDA approved 23 devices via the PMA pathway through June, an increase of 10 from the same point last year.
510(k) Clearances Show Modest Timeline Increases
The 510(k) clearance pathway, which remains the most frequently used route to market for medical devices, also experienced longer decision times, though the increase was less dramatic. The average time to clearance rose by seven to eight days, reaching roughly 156 days to decision in the first half of 2026.
The number of devices cleared through the 510(k) pathway is trending up 2.5% year over year, assuming the current pace holds, with a total of 1,669 clearances granted through June.
De Novo and Panel Track Pathways Also Affected
The agency granted 14 de novo classifications in the first half, a figure in line with last year's performance. However, the time to approval for de novo submissions increased by just over 8%.
Panel track approvals, which cover supplements for significant changes in a device's design or new indications for use, increased nearly 17% in the first half. Despite this growth in volume, the average number of days to approval also rose by 6.5%.
Industry Implications
Zimmerman characterized the increase in overall authorizations as encouraging, but emphasized a critical nuance for the medical device industry. For many stakeholders, and smaller companies in particular, "the timing to approval carries more importance in terms of the implications of capital runway and demand forecasting."
The report emerges against the backdrop of significant staffing changes at the FDA. The agency is currently seeking to hire more than 2,000 new staff members after cutting more than 3,000 roles last year. Those who remained at the FDA's device center have been grappling with heavy workloads and attrition, according to reporting from MedTech Dive.